(in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $12814 | $13287 | $8759 | $6711 |
Short term investments | $2 | $3 | $7 | $11 |
Net receivables | $11155 | $11412 | $11491 | $11473 |
Inventory | $4099 | $3981 | $4055 | $3833 |
Total current assets | $33002 | $33224 | $28852 | $26488 |
Long term investments | $304 | $275 | $288 | $257 |
Property, plant & equipment | $4989 | $4934 | $4943 | $4931 |
Goodwill & intangible assets | $87903 | $90694 | $95086 | $97068 |
Total noncurrent assets | $101709 | $102997 | $106515 | $108056 |
Total investments | $306 | $278 | $295 | $268 |
Total assets | $134711 | $136221 | $135367 | $134544 |
Current liabilities | ||||
Accounts payable | $30650 | $29658 | $27036 | $24789 |
Deferred revenue | ||||
Short long term debt | $7191 | $5115 | $5203 | $2801 |
Total current liabilities | $37841 | $34773 | $32239 | $27590 |
Long term debt | $52194 | $55631 | $55812 | $59292 |
Total noncurrent liabilities | $86473 | $89319 | $90230 | $93651 |
Total debt | $59385 | $60746 | $61015 | $62093 |
Total liabilities | $124314 | $124092 | $122469 | $121241 |
Shareholders' equity | ||||
Retained earnings | -$1000 | $933 | $1789 | $2393 |
Other shareholder equity | -$2305 | -$2353 | -$2252 | -$2232 |
Total shareholder equity | $10360 | $12094 | $12866 | $13274 |
(in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Current assets | ||||
Cash | $12814 | $9201 | $9746 | $8449 |
Short term investments | $2 | $28 | $84 | $30 |
Net receivables | $11155 | $11254 | $9977 | $8822 |
Inventory | $4099 | $3579 | $3128 | $3310 |
Total current assets | $33002 | $28463 | $27928 | $24173 |
Long term investments | $304 | $241 | $277 | $293 |
Property, plant & equipment | $4989 | $5672 | $5110 | $5248 |
Goodwill & intangible assets | $87903 | $99595 | $108330 | $116000 |
Total noncurrent assets | $101709 | $110342 | $118601 | $126392 |
Total investments | $306 | $269 | $361 | $323 |
Total assets | $134711 | $138805 | $146529 | $150565 |
Current liabilities | ||||
Accounts payable | $30650 | $8999 | $22699 | $20159 |
Deferred revenue | ||||
Short long term debt | $7191 | $4136 | $12495 | $8502 |
Total current liabilities | $37841 | $29538 | $35194 | $28661 |
Long term debt | $52194 | $59135 | $64189 | $77554 |
Total noncurrent liabilities | $86473 | $91980 | $95899 | $108807 |
Total debt | $59385 | $63271 | $76684 | $86056 |
Total liabilities | $124314 | $121551 | $131093 | $137468 |
Shareholders' equity | ||||
Retained earnings | -$1000 | $4784 | $3127 | $1055 |
Other shareholder equity | -$2305 | -$2199 | -$2899 | -$3117 |
Total shareholder equity | $10360 | $17254 | $15408 | $13076 |
(in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $13927 | $13865 | $12225 | |
Cost of revenue | $4240 | $3986 | ||
Gross Profit | $7460 | $9625 | $8239 | |
Operating activities | ||||
Research & development | $1733 | $2292 | ||
Selling, general & administrative | $3268 | $3039 | ||
Total operating expenses | $5053 | $5112 | $5471 | |
Operating income | $4513 | $2768 | ||
Income from continuing operations | ||||
EBIT | $3061 | $927 | ||
Income tax expense | $172 | $583 | $234 | |
Interest expense | -$423 | $454 | $454 | |
Net income | ||||
Net income | $1778 | $2024 | $239 | |
Income (for common shares) | $2024 | $239 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $54318 | $58054 | $45804 | |
Cost of revenue | $20415 | $17414 | $15387 | |
Gross Profit | $33903 | $40640 | $30417 | |
Operating activities | ||||
Research & development | $7675 | $6510 | $6557 | |
Selling, general & administrative | $12872 | $15260 | $11299 | |
Total operating expenses | $21146 | $22523 | $19054 | |
Operating income | $12757 | $18117 | $11363 | |
Income from continuing operations | ||||
EBIT | $7924 | $15512 | $5672 | |
Income tax expense | $1377 | $1632 | -$1224 | |
Interest expense | $1684 | $2044 | $2280 | |
Net income | ||||
Net income | $4863 | $11836 | $4616 | |
Income (for common shares) | $4863 | $11836 | $4616 |
(in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Net income | $822 | $1778 | $2024 | $239 |
Operating activities | ||||
Depreciation | $2076 | $2235 | $2260 | $2127 |
Business acquisitions & disposals | -$553 | -$157 | -$160 | -$353 |
Stock-based compensation | $125 | $130 | $179 | $313 |
Total cash flows from operations | $4753 | $7574 | $6319 | $4193 |
Investing activities | ||||
Capital expenditures | -$205 | -$219 | -$178 | -$175 |
Investments | -$20 | -$3 | -$2 | $3 |
Total cash flows from investing | -$800 | -$369 | -$341 | -$499 |
Financing activities | ||||
Dividends paid | -$2626 | -$2627 | -$2625 | -$2661 |
Sale and purchase of stock | $28 | $32 | $38 | -$1890 |
Net borrowings | -$1832 | -$2 | -$1002 | -$1351 |
Total cash flows from financing | -$4449 | -$2661 | -$3920 | -$6192 |
Effect of exchange rate | $23 | -$16 | -$10 | $8 |
Change in cash and equivalents | -$473 | $4528 | $2048 | -$2490 |
(in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Net income | $4863 | $11836 | $11542 | $4616 |
Operating activities | ||||
Depreciation | $8698 | $8467 | $8521 | $6471 |
Business acquisitions & disposals | -$1223 | -$794 | -$1902 | -$39610 |
Stock-based compensation | $747 | $671 | $692 | $753 |
Total cash flows from operations | $22839 | $24943 | $22777 | $17588 |
Investing activities | ||||
Capital expenditures | -$777 | -$695 | -$787 | -$798 |
Investments | -$22 | $92 | -$21 | $1464 |
Total cash flows from investing | -$2009 | -$623 | -$2344 | -$37557 |
Financing activities | ||||
Dividends paid | -$10539 | -$10043 | -$9261 | -$7716 |
Sale and purchase of stock | -$1792 | -$1225 | -$690 | -$769 |
Net borrowings | -$4187 | -$12433 | -$8414 | -$2703 |
Total cash flows from financing | -$17222 | -$24803 | -$19039 | -$11501 |
Effect of exchange rate | $5 | -$62 | -$97 | -$5 |
Change in cash and equivalents | $3613 | -$545 | $1297 | -$31475 |
AbbVie retains Humira market despite copycats (NYSE:ABBV)
Seeking Alpha
13 Apr 2024
|
What's Going On AbbVie Stock On Friday?
Benzinga via Yahoo Finance
12 Apr 2024
|
AbbVie Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance
11 Apr 2024
|
Top Stock Reports for AbbVie, Salesforce & General Electric
Zacks via Yahoo Finance
9 Apr 2024
|
Do These 3 Checks Before Buying AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend
Simply Wall St. via Yahoo Finance
7 Apr 2024
|
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance
5 Apr 2024
|
AbbVie Inc: An Exploration into Its Intrinsic Value
GuruFocus.com via Yahoo Finance
2 Apr 2024
|
AbbVie: An Undervalued Giant
GuruFocus.com via Yahoo Finance
27 Mar 2024
|
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks via Yahoo Finance
25 Mar 2024
|
13 Best Dividend-Paying Stocks Under $15
Insider Monkey via Yahoo Finance
24 Mar 2024
|
Market cap | $287.04B |
---|---|
Enterprise value | $333.61B |
Shares outstanding | 1.77B |
Revenue | N/A |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
P/E ratio | N/A |
---|---|
EV/Sales | N/A |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | N/A |
P/B ratio | 22.66 |
Book/Share | 7.17 |
Cash/Share | 7.26 |
EPS | N/A |
---|---|
ROA | N/A |
ROE | N/A |
Debt/Equity | 12.00 |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 0.87 |
Quick ratio | 0.76 |